Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209)
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. Part review of NICE technology appraisal guidance 86
NICE does not recommend imatinib at a dose of 600 or 800 mg a day for people with unresectable and/or metastatic GISTs whose disease has got worse after treatment with imatinib at a dose of 400 mg a day.
This guidance updates Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (NICE technology appraisal guidance 86).
Recommendation 1.5 in TA86 has been replaced. All the other recommendations in TA86 still apply. Please see the guidance for more information.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. There is not enough evidence from clinical trials to say how well an increased dose of imatinib works, or whether it works well enough to justify its cost, so NICE did not recommend it.
This page was last updated: 15 October 2013
- Web format
- Full Guidance (PDF)
- TA209 Imatinib ar gyfer tiwmorau stromatig gastro-berfeddol metastatig a/neu na ellir eu tynnu drwy lawdriniaeth: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.